¢¸
  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (1 ÆäÀÌÁö)
    1

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (2 ÆäÀÌÁö)
    2

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (3 ÆäÀÌÁö)
    3

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (4 ÆäÀÌÁö)
    4

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (5 ÆäÀÌÁö)
    5

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (6 ÆäÀÌÁö)
    6

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (7 ÆäÀÌÁö)
    7

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (8 ÆäÀÌÁö)
    8

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (9 ÆäÀÌÁö)
    9

  • º» ¹®¼­ÀÇ
    ¹Ì¸®º¸±â´Â
    9 Pg ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
¢º
Ŭ¸¯ : ´õ Å©°Ôº¸±â
  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (1 ÆäÀÌÁö)
    1

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (2 ÆäÀÌÁö)
    2

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (3 ÆäÀÌÁö)
    3

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (4 ÆäÀÌÁö)
    4

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (5 ÆäÀÌÁö)
    5

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (6 ÆäÀÌÁö)
    6

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (7 ÆäÀÌÁö)
    7

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (8 ÆäÀÌÁö)
    8

  • CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW   (9 ÆäÀÌÁö)
    9



  • º» ¹®¼­ÀÇ
    (Å« À̹ÌÁö)
    ¹Ì¸®º¸±â´Â
    9 Page ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
´õºíŬ¸¯ : ´Ý±â
X ´Ý±â
µå·¡±× : Á¿ìÀ̵¿

CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW

·¹Æ÷Æ® > ±âŸ ÀÎ ¼â ¹Ù·Î°¡±âÀúÀå
Áñ°Üã±â
Å°º¸µå¸¦ ´­·¯ÁÖ¼¼¿ä
( Ctrl + D )
¸µÅ©º¹»ç
Ŭ¸³º¸µå¿¡ º¹»ç µÇ¾ú½À´Ï´Ù.
¿øÇÏ´Â °÷¿¡ ºÙÇô³Ö±â Çϼ¼¿ä
( Ctrl + V )
ÆÄÀÏ : CLINICAL TRIAL SURVIVAL ANALYSIS OVERVIEW.pptx   [Size : 770 Kbyte ]
ºÐ·®   9 Page
°¡°Ý  1,000 ¿ø

Ä«Ä«¿À ID·Î
´Ù¿î ¹Þ±â
±¸±Û ID·Î
´Ù¿î ¹Þ±â
ÆäÀ̽ººÏ ID·Î
´Ù¿î ¹Þ±â


º»¹®/³»¿ë
_SLIDE_1_
CLINICAL TRIAL
SURVIVAL ANALYSIS
OVERVIEW
_SLIDE_2_
CLINICAL TRIAL
SURVIVAL ANALYSIS
OVERVIEW
_SLIDE_3_
CONTENTS

1. Clinical Trials

3. Phase 3

2. Phase 1

_SLIDE_4_
WHY CLINICAL TRIAL
Effectiveness of intervention to treat a disease
Safety of a new drug or device
Defining dose administration
Testing drug formulation
Exploring combination therapies
Evaluating effect of therapies on quality of life
_SLIDE_5_
BRIEF OF PHASES
Phase 1
Phase 2
Phase 3
Phase 4
No. of Participants
15-30
100-300
100 to thousands
Several hundreds to several thousands
Purpose
First in humans
safe dose
POC

1/3 fail

Determine efficacy
Safety
50% fail
Compare new agent with standard treatment
Safety
1/3 fail
P¡¦(»ý·«)


ÀÚ·áÁ¤º¸
ID : rain********
Regist : 2015-12-02
Update : 2015-12-02
FileNo : 15126952

Àå¹Ù±¸´Ï

¿¬°ü°Ë»ö(#)
CLINICAL   TRIAL   SURVIVAL   ANALYSIS   OVERVIEW  


ȸ»ç¼Ò°³ | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 ¤Ó ±¤ÁÖ±¤¿ª½Ã ±¤»ê±¸ ¹«Áø´ë·Î 326-6, 201È£ | äÈñÁØ | Åë½Å : ±¤»ê0561È£
Copyright¨Ï ¿Ã·¹¼ÒÇÁÆ® All rights reserved | Tel.070-8744-9518
°³ÀÎÁ¤º¸Ãë±Þ¹æħ ¤Ó °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 | Tel.070-8744-9518